CM
RETA

Castleark Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Castleark Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-26,085
Closed -$3.77M – 397
2020
Q1 		$3.77M Buy
+26,085
New +$5.04M 0.22% 121

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Castleark Management's RETA Position: Q2 2020 in Review

Castleark Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2020, closing a stake of 26,085 shares — an estimated $3.77M sold.

Castleark Management first reported a position in RETA in Q1 2020 and held it in 1 quarter. The position peaked at $3.77M in Q1 2020. 207 funds tracked by Wall St. Rank hold RETA as of Q2 2020.

  • Castleark Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2020 after selling out during the quarter.
  • Castleark Management sold 26,085 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2020, an estimated $3.77M.
  • Castleark Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2020 and held it in 1 quarter.
  • Castleark Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.77M in Q1 2020.
  • 207 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2020.

Based on Castleark Management's 13F filing for Q2 2020, filed 14 Aug 2020.